Biosimilars

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

Arrotex secures rights to an innovative, FDA-approved nanotech eye drop, promising faster, simpler recovery for thousands of surgical patients.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

A novel drug candidate targeting treatment-resistant kidney disease has begun its long journey through clinical trials, signaling a major strategic push.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

Wesley Pharmaceuticals launches a 503B-compliant NAD+ injection, promising quality in the booming anti-aging market amid scientific debate over its efficacy.

Global giant CSL taps Swiss biotech Memo Therapeutics in a landmark deal, signaling a major shift from plasma to lab-grown immunotherapies.

Positive study results for Alvotech's Entyvio biosimilar could disrupt the IBD market, promising lower costs for a blockbuster chronic care treatment.

DuPont launches a new reverse osmosis element promising dairy processors up to 50% higher productivity without changing their existing systems or practices.

Relay Therapeutics' experimental drug, zovegalisib, offers new hope for a common and hard-to-treat form of advanced breast cancer with a promising safety profile.

A new therapy for a rare blood cancer gets a major boost from the FDA, offering hope for thousands of myelofibrosis patients with limited options.

A new partnership promises up to 22% savings for employers by integrating deep pharmacy expertise, tackling one of healthcare's most complex challenges.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.